15 Jul 2022

EMCR news 12 July from Miles Andrews

Dr Miles Andrews, CCS EMCR rep

Update from Dr Miles Andrews, CCS EMCR Representative
12 July 2022

It’s been a little while since our last newsletter, so here is your list of programs, events and grants that might be of interest to you, together with links to Monash ECR portals and gateways.

Congratulations to GIN Hub Round 2 pitch winners Idrish Ali and Evelyn Tsantikos

Drs Idrish Ali and Evelyn Tsantikos won The Pitch

The Gastroenterology-Immunology-Neuroscience (GIN) Hub news update for 13 July, compiled by Alana Auden

Congratulations Drs Idrish Ali and Evelyn Tsantikos for being awarded funding in Round 2 of The Pitch for their project "Role of granulocyte-colony-stimulating factor signalling in epilepsy". 

This collaborative project between Idrish (O’Brien group - Neuroscience) and Evelyn (Hibbs group - Immunology) beat some stiff competition in the GIN Hub seed funding scheme. We look forward to seeing what exciting EMCR collaborative projects are submitted in Round 3, which is already open and closes on Wednesday 10 August. Further details on how to apply for The Pitch can be found here

The “risky” business of thromboembolic events for patients with intravenous immunoglobulin treatment

Dr Mahima Kapoor is the first author on a study which shows higher
risk for patients who have suffered clotting events from a particular
treatment, intravenous immunoglobulin.

by Dr Loretta Piccenna, Department of Neuroscience

An important analysis using the UK Biobank published this month by researchers in the Neuromuscular group in the Department of Neuroscience has shown a three-fold higher risk of blood clots, or thromboembolic events (TEEs), in patients with a prior history of these events when they were treated with intravenous immunoglobulin (IVIg) (1).

Kidney transplantation for First Nations Australians: from ‘These sorts of people don’t do very well’ to ‘Hunting Transplants’ and ‘Return to Country’

Patient precentors Peter Henwood, Neil Wilkshire and
David Croker from Purple House in the Northern Territory
gave first hand accounts of the education process. Video
by Dr Angela Burge, CCS GEDI committee

On Fri 8 July, Professor Paul Lawton shared his valuable insights as part of the NAIDOC week Central Clinical School Seminar Series. We were fortunate that he was able to be joined by a First Nation Peoples panel, with extra special thanks to Peter Henwood, David Croker and Neil Wilkshire from Purple House direct from the Northern Territory (NT), who provided a firsthand perspective on the challenges and opportunities that the health system faces in providing adequate care to the huge number of Australians affected by kidney disease. See CCS GEDI web page for video.

Importantly, the significant lack of parity between renal transplants in indigenous renal patients, dramatically reducing their survival rates in the NT, was highlighted as a critical national healthcare issues that needs to be immediately addressed.

Prof Paul Myles receives award from Liverpool Society of Anaesthetists

Prof Paul Myles (left) being presented with the T.Cecil Gray BJA
Medal by Dr Frank Potter after giving the 6th T.Cecil Gray lecture.

Congratulations to Professor Paul Myles who was invited to give the prestigious biennial T. Cecil Gray BJA lecture by the Liverpool Society of Anaesthetists. His lecture topic was 'Defining and Measuring the Quality of Recovery after Surgery'.

Prof Myles said, "It was an honour to be invited to give this lecture, and I guess I was being acknowledged for my role in large clinical trials and outcomes research in anaesthesia."

See Prof Myles' review article on the topic:

Myles PS. More than just morbidity and mortality - quality of recovery and long-term functional recovery after surgery. Anaesthesia. 2020 Jan;75 Suppl 1:e143-e150. doi: 10.1111/anae.14786.

14 Jul 2022

Participants sought: Cognitive Behavioural Therapy (CBT) for Migraine in Multiple Sclerosis

See flier for this study on CBT for migraine in MS

Participants are sought for a research study investigating the use of Cognitive Behavioural Therapy (CBT) for migraine in Multiple Sclerosis (MS). EOI form link, and see more detail below.

We believe it is important to develop a therapy that is tailored to people with both migraine and MS. Our aim is to learn whether CBT is accepted by patients, and whether it has the potential to improve migraines, and in turn benefit quality of life, fatigue, sleep, anxiety, and depressive symptoms, which can occur more frequently for people with migraine and MS.

21 June - 11 July 2022 Central Clinical School recent publications

Study shows gluten not the culprit for mental
or physical symptoms in non-coeliac patients
Recent publications featuring research as notified by PubMed during 21 June - 11 July 2022 from Central Clinical School affiliated researchers in the following departments.

The most recent validated publications for the school and departments can be seen on their publications pages, linked to from the headings below. Otherwise, read down the entry for recent notifications. The below is not a comprehensive list.

11 Jul 2022

EMCR event | Changing lanes: Navigating different career paths in academia, industry and beyond

Join us next Thursday 21 July for "Changing lanes: Navigating different career paths in academia, industry and beyond", an online panel event for A+ EMCRs featuring three senior researchers and industry executives, Associate Professor Menno van Zelm (Monash University, Dr Bev Menner (CSL) and Dr Sue Forrest (mexec). Register now and see more detail below.

A+ Changing Lanes online panel event

World first Australian and New Zealand trial of cannabidiol transdermal gel for the most common hard-to-treat epilepsy type in adults

Professor Terry O'Brien has led a trial using transdermal CBD gel
in adults with focal epilepsy. After 6 months of treatment, over half
the patients experienced a 50%+ reduction in seizures. JAMA study

Medicinal cannabis-based treatments are emerging as promising complementary approaches to improving seizure control in patients with difficult to treat epilepsy. In 2018 the US Food and Drug Administration (FDA) approved the use of a prescription cannabidiol medicine for the treatment of two rare epilepsy diseases that cause treatment resistant seizures, Lennox-Gastaut Syndrome and Dravet syndrome, that predominantly affect children. 

Related Posts Plugin for WordPress, Blogger...